Tag: Hla b 5701

The U.S. Food and Drug Administration (FDA) and other health authorities have issued a boxed warning for abacavir, primarily due to the risk of a severe, potentially fatal hypersensitivity reaction (HSR). This means that **why abacavir is a hazardous drug** is a critical consideration in clinical practice and for patient safety. This is compounded by the fact that the reaction is strongly correlated with a specific genetic marker.

According to the FDA, serious and sometimes fatal hypersensitivity reactions have occurred with abacavir, making patient screening critical for safety. Understanding **who cannot take abacavir** is essential for all healthcare providers and individuals beginning or resuming therapy with this medication.

The abbreviation **ABC** is used in a clinical setting to refer to the antiretroviral medication **abacavir**, a cornerstone of combination therapies for HIV-1 infection. Knowing which drug is ABC is particularly crucial due to the risk of a serious, potentially fatal hypersensitivity reaction that can occur in some individuals.